Nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson’s disease

1. European Association for the Study of the Liver: EASL clinical practice guidelines: Wilson’s disease. J Hepatol. 2012;56:671-85.10.1016/j.jhep.2011.11.007Search in Google Scholar

2. Delangle P, Mintz E.Chelation therapy in Wilson’s disease: from D-penicillamine to the design of selective bioinspired intracellular Cu(I) chelators. DaltonTrans. 2012;41(21):6359-70. doi: 10.1039/c2dt12188c10.1039/c2dt12188cSearch in Google Scholar

3. Sözeri E, Feist D, Ruder H, Schärer K. Proteinuria and other renal functions in Wilson’s disease. Pediatr Nephrol. 1997;11(3):307-11. PMID:920317810.1007/s004670050282Search in Google Scholar

4. Mareček Z, Brůha R. Wilsons disease. Vnitr Lek. 2013; 59(7):578-83. PMID:23909262Search in Google Scholar

5. Ranucci G, Di Dato F, Spagnuolo MI, Vajro P, Iorio R.Zinc monotherapy is effective in Wilson’s disease patients with mild liver disease diagnosed in childhood: a retrospective study. Orphanet J Rare Dis. 2014 Mar; 25:9(1):41. doi: 10.1186/1750-1172-9-4110.1186/1750-1172-9-41Search in Google Scholar

6. Siafakas CG, Jonas MM, Alexander S, Herrin J, Furuta GT. Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson’s disease. Am J Gastroenterol.1998 Dec; 93(12):2544-6.PMID:986042310.1111/j.1572-0241.1998.00715.xSearch in Google Scholar

7. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML.Wilson’s disease. Lancet. 2007 Feb 3;369(9559):397-408. PMID:17276780Search in Google Scholar

8. Khalil-Manesh F, Price RG. Effect of D-penicillamine on glomerular basement membrane, urinary N-acetyl- beta-D-glucosaminidase and protein excretion in rats. Toxicology. 1983;26(3-4):325-34.10.1016/0300-483X(83)90093-8Search in Google Scholar

9. Wiggelinkhuizen M, Tilanus ME, Bollen CW, Houwen RH. Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Aliment Pharmacol Ther. 2009; 29(9):947-58. doi: 10.1111/j.1365-2036.2009.03959.x10.1111/j.1365-2036.2009.03959.xSearch in Google Scholar

10. Das SK, Ray K. Wilson’s Disease: An Update. Nat Clin Pract Neurol. 2006;2(9):482-493. PMID:1693261310.1038/ncpneuro0291Search in Google Scholar

11. Chang H, Xu A, Chen Z, Zhang Y, Tian F, Li T.Longterm effects of a combination of D-penicillamine and zinc salts in the treatment of Wilson’s disease in children. Exp Ther Med. 2013 Apr;5(4):1129-1132.PMID:23599735 [PubMed] PMCID:PMC362859410.3892/etm.2013.971Search in Google Scholar

12. Grasedyck K. D-penicillamine-side effects, pathogenesis and decreasing the risks. Z Rheumatol. 1988; 47(1):17-9. PMID:3063003Search in Google Scholar

13. Huster D. Wilson disease. Best Pract Res Clin Gastroenterol. 2010 Oct;24(5):531-9. doi: 10.1016/j. bpg.2010.07.014Search in Google Scholar

14. Rodríguez B, Burguera J, Berenguer M.Response to different therapeutic approaches in Wilson disease. A long-termfollow up study.Ann Hepatol. 2012 Nov-Dec; 11(6):907-14. PMID: 2310945510.1016/S1665-2681(19)31417-6Search in Google Scholar

15. Ping CC, Hassan Y, Aziz NA, Ghazali R, Awaisu A.Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson’s disease. J Clin Pharm Ther. 2007 Feb;32(1):101-7. PMID: 1728679410.1111/j.1365-2710.2007.00794.xSearch in Google Scholar

16. Dong QY, Wu ZY. Advance in the pathogenesis and treatment of Wilson disease. Transl Neurodegener. 2012 Nov;1(1):23. doi: 10.1186/2047-9158-1-2310.1186/2047-9158-1-23Search in Google Scholar

17. Lowette KF, Desmet K, Witters P, Laleman W, Verslype C, Nevens F, et al. Wilson’s disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine.Eur J Gastroenterol Hepatol. 2010 May;22(5):564-71. doi: 10.1097/MEG.0b013e3283353df810.1097/MEG.0b013e3283353df8Search in Google Scholar

18. Weiss KH, Thurik F, Gotthardt DN, Schäfer M, Teufel U, Wiegand F, et al. EUROWILSON Consortium. Efficacy and safety of oral chelators in treatment of patients with Wilson Disease. Clin Gastroenterol Hepatol.2013; 11(8):1028-35. e1-2. doi: 10.1016/j.cgh.2013.03.01210.1016/j.cgh.2013.03.012Search in Google Scholar

19. Członkowska A, Litwin T, Karliński M, Dziezyc K, Chabik G, Czerska M. D-penicillamine versus zinc sulfate as first-line therapy for Wilson’s disease. Eur J Neurol. 2014 Apr;21(4):599-606. doi: 10.1111/ ene.1234810.1111/ene.12348Search in Google Scholar

20. Sternlieb I, Scheinberg H. Prevention of Wilson’s Disease in Asymptomatic Patients. N Engl J Med. 1968;278:352-9. PMID: 563564610.1056/NEJM196802152780702Search in Google Scholar

21. Habib GS, Saliba W, Nashashibi M, Armali Z. Penicillamine and nephrotic syndrome. Eur J Intern Med. 2006 Aug;17(5):343-8. PMID: 1686401010.1016/j.ejim.2006.03.001Search in Google Scholar

22. Scheinberg IH, Sternlieb I. Wilson disease. in Major problems in internal medicine. eds Lloyd H, Smith J (Saunders, Philadelphia), 1984; 134-49Search in Google Scholar

23. Adams DA, Goldman R, Maxwell MH, Latta H. Nephrotic Syndrome Associated with Penicillamine Therapy of Wilson’s Disease. Am J Med. 1964 Feb;36:330-6. PMID: 1412470010.1016/0002-9343(64)90096-8Search in Google Scholar

24. Tesar V, Zima T, Kalousová M. Pathobiochemistry of nephrotic syndrome. Adv Clin Chem. 2003;37:173-218. PMID: 1261970810.1016/S0065-2423(03)37009-XSearch in Google Scholar

25. Ozçakar Z, Ekim M, Ensari A, Kuloglu Z, Yüksel S, Acar B, et al. Membranoproliferative glomerulonephritis in a patient with Wilson’s disease. J Nephrol. 2006;19(6):831-3. PMID: 17173260Search in Google Scholar

26. Koraishy FM, Cohen RA, Israel GM, Dahl NK. Cystic Kidney Disease in a Patient With Systemic Toxicity From Long-term d-Penicillamine Use. Am J Kidney Diseases. 2013 Oct; 62(4): 806-809. doi: 10.1053/j. ajkd.2013.04.017Search in Google Scholar

27. Davis P, Bleehen SS. D-penicillamine in the treatment of rheumatoid arthritis and progressive systemic sclerosis. Br J Dermatol. 1976 Jun;94(6):705-11. PMID:77982110.1111/j.1365-2133.1976.tb05174.x779821Search in Google Scholar

28. Dzieżyc K, Karliński M, Litwin T, Członkowska A. Compliant treatment with anti-copper agents prevents clinically overt Wilson’sdisease in pre-symptomatic patients. Eur J Neurol. 2014 Feb;21(2):332-7. doi: 10.1111/ene.1232010.1111/ene.12320Search in Google Scholar

29. Sanches MR. Miscellaneous Treatments: Thalidomide, Potassium Iodide, Levamisole, Clofazimine, Colchicine, and D-Penicillamine. Clin Dermatol. 2000;18:131-45. PMID: 1070109510.1016/S0738-081X(99)00103-0Search in Google Scholar

30. Walshe JM. Monitoring copper in Wilson’s disease. Adv Clin Chem. 2010;50:151-63. PMID: 20521445 10.1016/S0065-2423(10)50008-8Search in Google Scholar